Dijon

• Phase 2, Multicenter, Open label, Platform Study investigating ASP3082 in patients with Metastatic/Locally Advanced Non-Small-Cell Lung Canc … Recruiting
  2025-522533-54-00 4 2026-03-17 Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal ad
• A clinical study to find the optimal dose of an investigational treatment called BNT323 when used in combination with another investigationa … Recruiting
  2024-517979-20-00 9 2026-03-04 Advanced Breast Cancer Metastatic Breast Cancer
• Study aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combin … Recruiting
  2023-506291-28-00 5 2026-03-02 Patient with locally advanced/metastatic, MSI-H/dMMR gastric cancer
• PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai … Recruiting
  2025-522108-26-00 4 2026-02-19 métastatique colorectal cancer
• Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting
  2025-521805-41-00 5 2026-02-18 Patients with HER2-positive, locally advanced or metastatic breast can
• A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped respon … Recruiting
  2025-521880-10-00 9 2026-02-16 Metastatic castrate resistant prostate cancer (mCRPC)
• Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated … Recruiting
  2024-515948-23-00 5 2026-02-06 Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
• A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of Obinutuzumab in the treatment of non-infectious … Recruiting
  2023-508930-33-00 4 2026-01-30 Non-infectious active cryoglobulinemia vasculitis who are either refra
• A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Intravenous Mirvetuximab Soravtansin … Recruiting
  2025-521606-18-00 4 2026-01-29 Ovarian Cancer
• NUCastle - Nintedanib treatment in Unicentric Castleman disease Recruiting
  2023-510253-42-00 4 2026-01-28 Adult patients aged 18 and over with unicentric hyalino-vascular Castl
• Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o … Recruiting
  2024-515658-26-00 5 2026-01-21 Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
• FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients prev … Recruiting
  2023-505781-28-00 4 2026-01-20 Patients with Waldenstrom macroglobulinemia and have received at least
• A Study to test ALE.P03 in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors Recruiting
  2025-521441-24-00 7 2026-01-19 Advanced or Metastatic Solid Tumors
• LA-HCM : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients with Abnormal Left Atrial Strain : A Randomized M … Recruiting
  2024-511084-28-00 11 2026-01-12 Hypertrophic Cardiomyopathie
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran … Recruiting
  2024-511437-35-00 10 2026-01-05 Patients aged 18-65 years old with newly diagnosed previously untreate
• Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervou … Recruiting
  2025-521144-38-00 4 2025-12-23 Primary Central Nervous System Lymphoma
• OBI-WAN : Obinutuzumab for remission induction in patients with relapsing PR3-ANCA granulomatosis with polyangiitis (Wegener’s). Phase 2 pro … Recruiting
  2022-501557-36-00 4 2025-12-19 PR3-ANCA granulomatosis with polyangiitis (Wegener’s)
• A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia Recruiting
  2025-521692-31-00 5 2025-12-19 Chronic Primary Immune Thrombocytopenia
• Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study) Recruiting
  2024-518385-26-01 5 2025-12-18 Polymyalgia Rheumatica (PMR)
• WIthdrawal of DUpilumab in Severe Asthma : a randomised non-inferiority-controlled trial Recruiting
  2024-516789-13-00 6 2025-12-15 Severe asthma
• ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid … Recruiting
  2025-522395-92-00 5 2025-12-15 metastatic oeso-gastric adenocarcinoma
• EPIK-P4: A Phase II single-arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patien … Recruiting
  2024-519960-42-00 4 2025-12-11 PIK3CA-Related Overgrowth Spectrum (PROS)
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
• A 52-week study of rilzabrutinib efficacy and safety compared to placebo in adults diagnosed with IgG4-related disease Recruiting
  2025-521398-15-00 5 2025-12-04 Immune system diseases

Showing 169–192 of 813 trials